Hexavest Inc. increased its stake in shares of Eli Lilly and Co (NYSE:LLY) by 1.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,360,139 shares of the company’s stock after purchasing an additional 22,492 shares during the quarter. Eli Lilly and makes up 1.3% of Hexavest Inc.’s holdings, making the stock its 11th largest position. Hexavest Inc. owned 0.12% of Eli Lilly and worth $114,877,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Accredited Investors Inc. grew its holdings in Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after acquiring an additional 14 shares during the period. Oakworth Capital Inc. grew its holdings in Eli Lilly and by 0.3% during the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the period. Sfmg LLC grew its holdings in Eli Lilly and by 0.5% during the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. grew its holdings in Eli Lilly and by 0.7% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC grew its holdings in Eli Lilly and by 0.8% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after acquiring an additional 24 shares during the period. Hedge funds and other institutional investors own 76.35% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock valued at $22,041,236 over the last three months. 0.20% of the stock is currently owned by insiders.
Shares of Eli Lilly and Co (NYSE:LLY) traded down $0.39 during midday trading on Friday, hitting $85.82. The stock had a trading volume of 4,445,800 shares, compared to its average volume of 3,173,292. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market capitalization of $94,440.00, a PE ratio of 40.87, a PEG ratio of 1.68 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm posted $0.88 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. analysts expect that Eli Lilly and Co will post 4.22 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.62%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently 99.05%.
Several analysts have commented on the company. BMO Capital Markets reissued a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the company a “buy” rating in a research report on Tuesday. Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and raised their target price for the company from $86.98 to $95.00 in a research report on Tuesday. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $92.75.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/01/19/hexavest-inc-acquires-22492-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.